HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Maternal intake of folate during pregnancy and risk of cerebral palsy in the MOBAND-CP cohort.

AbstractBACKGROUND:
Folate prevents neural tube defects and may play a role in some neurodevelopmental disorders.
OBJECTIVES:
We investigated whether higher intakes of periconceptional or midpregnancy folate, as recommended, were associated with a reduced risk of offspring cerebral palsy (CP).
METHODS:
We included participants from the Nordic collaboration cohort consisting of mother-child dyads in the Danish National Birth Cohort and the Norwegian Mother, Father, and Child Cohort Study [combined as MOthers and BAbies in Norway and Denmark (MOBAND-CP)]. A total of 190,989 live-born children surviving the first year of life were included. Missing covariate data were multiply imputed. Our exposures were defined as any or no folic acid supplementation in gestational weeks (GWs) -4 to 8 (periconceptional), 9 to 12, and -4 to 12, and supplemental, dietary, and total folate during midpregnancy (GWs 22-25). CP overall and the unilateral and bilateral spastic subtypes, as well as CP with low or moderate/high gross motor function impairments, were our outcomes of interest.
RESULTS:
Periconceptional folic acid supplementation was not associated with CP [adjusted odds ratio (aOR), 1.02; 95% CI: 0.82-1.28]. However, supplementation in GWs 9 to 12 was associated with a reduced risk of CP (aOR, 0.74; 95% CI: 0.57-0.96), and inverse associations were indicated for both the unilateral (aOR, 0.68; 95% CI: 0.46-1.02) and bilateral (aOR, 0.70; 95% CI: 0.49-1.02) spastic subtypes, although the associations were not statistically significant. Supplemental or dietary folate in midpregnancy alone were not associated with CP. Strong inverse associations were observed with low gross motor function impairment (aOR, 0.49; 95% CI: 0.29-0.83), while for unilateral CP the aOR was 0.63 (95% CI: 0.34-1.22) for intakes of ≥500 compared to ≤199 dietary folate equivalents/day during midpregnancy.
CONCLUSIONS:
Our findings suggest that folate intakes in GWs 9 to 12 and midpregnancy were associated with lower risks of CP, while no association was observed for periconceptional supplementation.
AuthorsJonathan Groot, Tanja G Petersen, Pål Suren, Anne Lise Brantsæter, Peter Uldall, Torben Martinussen, Charlotta Granström, Sjurdur F Olsen, Allen J Wilcox, Katrine Strandberg-Larsen
JournalThe American journal of clinical nutrition (Am J Clin Nutr) Vol. 115 Issue 2 Pg. 397-406 (02 09 2022) ISSN: 1938-3207 [Electronic] United States
PMID34687208 (Publication Type: Journal Article, Research Support, N.I.H., Intramural, Research Support, Non-U.S. Gov't)
Copyright© The Author(s) 2021. Published by Oxford University Press on behalf of the American Society for Nutrition.
Chemical References
  • Folic Acid
Topics
  • Adult
  • Cerebral Palsy (epidemiology, prevention & control)
  • Cohort Studies
  • Dietary Supplements
  • Female
  • Folic Acid (administration & dosage)
  • Humans
  • Infant, Newborn
  • Odds Ratio
  • Preconception Care (statistics & numerical data)
  • Pregnancy
  • Prenatal Care (statistics & numerical data)
  • Risk Factors
  • Scandinavian and Nordic Countries (epidemiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: